INTS Intensity Therapeutics
- 3.770
- +0.020+0.53%
Intensity Therapeutics News
Intensity Therapeutics Got Nasdaq Letter Due To Resignation Of Daniel Donovan From Audit Committee, Co Not Compliant With Nasdaq Listing Rule 5605
Intensity Therapeutics Got Nasdaq Letter Due To Resignation Of Daniel Donovan From Audit Committee, Co Not Compliant With Nasdaq Listing Rule 5605
Portage Biotech Completes Monetization of Intensity Therapeutics (INTS) Shares
WESTPORT, Conn., March 26, 2024 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ:PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as monotherapy and in combination, today
Intensity Therapeutics Price Target Maintained With a $12.00/Share by Benchmark
Intensity Therapeutics Price Target Maintained With a $12.00/Share by Benchmark
Benchmark Reiterates Speculative Buy on Intensity Therapeutics, Maintains $12 Price Target
Benchmark analyst Robert Wasserman reiterates Intensity Therapeutics with a Speculative Buy and maintains $12 price target.
Intensity Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/21/2024 130.77% Benchmark → $12 Reiterates Speculative Buy → Speculative Buy 11/14/2023 130.77% Benchma
Intensity Therapeutics Reports FY23 EPS $(1.38) Vs $(2.22) YoY
Year-End 2023 Financial ResultsResearch and development expenses were $4.8 million for the year ended December 31, 2023, compared to $5.1 million for the same period in 2022. The decrease was primaril
Intensity Therapeutics 2023 Year-End Cash And Investments $14.8M
Intensity Therapeutics 2023 Year-End Cash And Investments $14.8M
Intensity Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate Update
Intensity Therapeutics, Inc. ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase immune system recognition of cancers, announces full year 2023 financial results and provides a review of 2023 accomplishments and anticipated upcoming developments.
12 Health Care Stocks Moving In Monday's Intraday Session
GainersRegencell Bioscience (NASDAQ:RGC) shares rose 130.9% to $10.39 during Monday's regular session. The company's market cap stands at $135.2 million. TC BioPharm (Holdings) (NASDAQ:TCBP) shares in
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
GainersNKGen Biotech (NASDAQ:NKGN) shares increased by 69.4% to $1.46 during Wednesday's pre-market session. The market value of their outstanding shares is at $31.9 million. Creative Medical Tech (NA
Intensity Therapeutics to Present at the 2024 BIO CEO & Investor Conference
Intensity Therapeutics is a late-stage clinical biotechnology company that applies novel engineered chemistry to turn "cold" tumors "hot" by enabling its aqueous cytotoxic-containing drug product, INT230-6, to mix and saturate the dense, high-fat pressurized environment of the tumor.
Intensity Therapeutics Unveils New Incentive Compensation Plan
Intensity Therapeutics To Initiate Phase 3 Sarcoma Trial In H1 - Quick Facts
Intensity Therapeutics Gets FDA Green Light for Phase 3 Study
By Colin Kellaher Intensity Therapeutics has received U.S. Food and Drug Administration approval to launch a Phase 3 study of its lead drug candidate INT230-6 in soft tissue sarcoma. The Shelton, Co
Intensity Therapeutics (NASDAQ:INTS) Is In A Good Position To Deliver On Growth Plans
12 Health Care Stocks Moving In Thursday's Pre-Market Session
GainersCingulate (NASDAQ:CING) stock moved upwards by 188.5% to $11.51 during Thursday's pre-market session. The market value of their outstanding shares is at $10.7 million. SenesTech (NASDAQ:SNES) s
12 Health Care Stocks Moving In Friday's After-Market Session
GainersAlaunos Therapeutics (NASDAQ:TCRT) stock rose 20.9% to $0.06 during Friday's after-market session. The company's market cap stands at $13.2 million. Impel Pharmaceuticals (NASDAQ:IMPL) shares r
12 Health Care Stocks Moving In Thursday's Intraday Session
GainersTriSalus Life Sciences (NASDAQ:TLSI) stock moved upwards by 38.3% to $8.23 during Thursday's regular session. The market value of their outstanding shares is at $216.5 million. Immix Biopharma
CAN, TPIC and MOTS Among Mid-day Movers
Intensity Therapeutics: John Wesolowski Will Remain as Principal Acctg Officer and Controller >INTS
Intensity Therapeutics: John Wesolowski Will Remain as Principal Acctg Officer and Controller >INTS
Analysis
Price Target
No Data
